Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01596400 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
A Phase 1 study of Chemotherapy-induced Nausea and Vomiting, sponsored by Kyowa Kirin Pharmaceutical Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 12
- Study locations
NCT01596400 is a Phase 1 study of Chemotherapy-induced Nausea and Vomiting that has completed, run by Kyowa Kirin Pharmaceutical Development. The registered enrollment target is 19 participants, below the 443-participant average among 3 other Chemotherapy-induced Nausea and Vomiting trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT01596400, a Phase 1 study of Chemotherapy-induced Nausea and Vomiting, has completed, sponsored by Kyowa Kirin Pharmaceutical Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
Conditions Studied
Interventions
- DRUG granisetron transdermal system
- DRUG Granisetron IV
Study Locations (12)
Florida
- University of Florida - Gainesville
- Nemours Children's Clinic - Jacksonville
- University of South Florida - Tampa
California
- David Geffen School of Medicine at UCLA - Los Angeles
- Children's Hospital of Orange County - Orange
Texas
- UTSW/Childrens Medical Center - Dallas
- UT Southwestern Medical Center - Dallas
Washington
- Providence Sacred Heart Medical Center and Children's Hospital - Spokane
- Madigan Army Medical Center - Tacoma
Colorado
- Children's Hospital Colorado, Center for Cancer and Blood Disorders - Aurora
Mississippi
- University of Mississippi Medical Center - Jackson
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01596400
The ClinicalTrials.gov registry entry for NCT01596400 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 3 other Chemotherapy-induced Nausea and Vomiting trials with a reported enrollment target (96% lower). The listed sponsor is Kyowa Kirin Pharmaceutical Development, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chemotherapy-induced Nausea and Vomiting appearing as the primary indexed condition, and to 2 interventions - of which granisetron transdermal system is the first listed.
NCT01596400 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT01596400 about?
NCT01596400 is a clinical study titled "Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years". The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
What is the current status of trial NCT01596400?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-05. Estimated completion is 2016-12.
What conditions does trial NCT01596400 study?
This clinical trial studies the following conditions: Chemotherapy-induced Nausea and Vomiting.
What interventions are being tested in trial NCT01596400?
The interventions under investigation include: granisetron transdermal system (DRUG), Granisetron IV (DRUG).
Who is sponsoring clinical trial NCT01596400?
This trial is sponsored by Kyowa Kirin Pharmaceutical Development, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01596400 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Mississippi, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Nausea and Vomiting
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
RECRUITING · NA
-
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
COMPLETED · Phase 3
-
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.